Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 7/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14816285 | 1.00 | PDE4B (0.31) | PDE4BP2RX3 | |
| SCHEMBL14800247 | 0.82 | P2RX3 (0.37) | PDE4BP2RX3 | |
| SCHEMBL14800249 | 0.82 | P2RX3 (0.37) | PDE4BP2RX3 | |
| SCHEMBL14815909 | 0.81 | P2RX3 (0.31) | P2RX3 | |
| SCHEMBL14815908 | 0.81 | P2RX3 (0.31) | P2RX3 | |
| SCHEMBL14828639 | 0.81 | P2RX3 (0.31) | P2RX3 | |
| SCHEMBL14800394 | 0.79 | CDK4 (0.37) | — | |
| SCHEMBL14800393 | 0.79 | CDK4 (0.37) | — | |
| SCHEMBL14815684 | 0.76 | TBXAS1 (0.38) | PDE4BP2RX3 | |
| SCHEMBL14815682 | 0.76 | TBXAS1 (0.38) | PDE4BP2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760856-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-09-14 | — | — | EP | disclosed |
| US-8722670-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130085138-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085138-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | PDE4B 2566/4885P2RX3 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.